MIT and Harvard scientists have developed CAR-NK immune cells that attack tumours while evading the body's defences. Unlike traditional CAR-T therapy, these "off-the-shelf" cells can be mass-produced, stored, and used immediately, showing strong tumour-killing effects with fewer side effects in mice. Clinical trials are planned to bring faster, safer cancer treatments to patients.